Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari
In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics’ Filspari (sparsentan) for treating primary IgA nephropathy (IgAN) in adults at risk of disease progression. This decision, announced on September 5, 2024, marks a significant milestone in the battle against this rare kidney disease, offering a new […]